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Abstract
11b-Hydroxysteroid dehydrogenases (11beta-HSD) modulate mineralocorticoid receptor transactivation by glucocorticoids
and regulate access to the glucocorticoid receptor. The isozyme 11beta-HSD2 is selectively expressed in mineralocorticoid
target tissues and its activity is reduced in various disease states with abnormal sodium retention and hypertension,
including the apparent mineralocorticoid excess. As 50% of patients with essential hypertension are insulin resistant and
hyperinsulinemic, we hypothesized that insulin downregulates the 11beta-HSD2 activity. In the present study we show that
insulin reduced the 11beta-HSD2 activity in cancer colon cell lines (HCT116, SW620 and HT-29) at the transcriptional level, in
a time and dose dependent manner. The downregulation was reversible and required new protein synthesis. Pathway
analysis using mRNA profiling revealed that insulin treatment modified the expression of the transcription factor family C/
EBPs (CCAAT/enhancer-binding proteins) but also of glycolysis related enzymes. Western blot and real time PCR confirmed
an upregulation of C/EBP beta isoforms (LAP and LIP) with a more pronounced increase in the inhibitory isoform LIP. EMSA
and reporter gene assays demonstrated the role of C/EBP beta isoforms in HSD11B2 gene expression regulation. In addition,
secretion of lactate, a byproduct of glycolysis, was shown to mediate insulin-dependent HSD11B2 downregulation. In
summary, we demonstrate that insulin downregulates HSD11B2 through increased LIP expression and augmented lactate
secretion. Such mechanisms are of interest and potential significance for sodium reabsorption in the colon.
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Introduction
The mineralocorticoid receptor (MR) is essential for renal
sodium handling in epithelial tissues such as colon and kidney and
for blood pressure control in humans. The physiological ligand of
the MR is aldosterone [1]. Another adrenal steroid, cortisol,
exhibits a similar affinity and transactivation potential for the MR
as aldosterone. Serum concentrations of cortisol are 100 to 1000
fold higher than aldosterone. The mechanism allowing aldoste-
rone to be the preferred ligand for the MR in vivo, despite the
higher concentrations of cortisol is an enzyme which inactivates
cortisol, specifically in MR expressing cells [2]. This enzyme, 11b-
hydroxysteroid dehydrogenase type 2 (11beta-HSD2) is encoded
by the HSD11B2 gene and converts biologically active cortisol
into cortisone, a steroid with negligible affinity and activation
potential for the MR [3]. Thus, a reduced activity of 11beta-
HSD2 causes cortisol-mediated MR activation, leading to renal
sodium retention, suppression of renin and a salt-sensitive increase
in blood pressure [4,5].
Many patients with type 2 diabetes have low renin activity in
plasma and are salt-sensitive [6–8]. Furthermore, we recently
observed an association of salt-sensitivity and reduced activity of
11beta-HSD2 in offspring of type 2 diabetic patients [9]. Thus, it is
reasonable to speculate that insulin downregulates HSD11B2, and
by this mechanism, causes cortisol-mediated renal or colonic
sodium retention with consequent renin suppression.
It has been shown that that insulin and hyperinsulinemia
regulate the family of transcription factors CCAAT/enhancer
binding proteins (C/EBPs) [10,11] and that members of this family
control the transcription of HSD11B1 [12–14]. The analysis of the
promoter of the HSD11B2 gene by the transcription factor
database (TRANSFAC) program revealed several putative binding
sites for C/EBPs at positions 24362 bp, 21985 bp, 2177 bp and
at 2198 bp from the transcriptional starting site of human
HSD11B2 gene. Therefore, we hypothesized that insulin down-
regulates HSD11B2 through C/EBPs.
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Material and Methods
Reagents and supplies
Cell culture material was from Becton Dickinson Labware
(Basel, Switzerland) and Corning (Bodenheim, Germany). Dul-
becco’s Modified Eagle’s Medium (DMEM) and Mc Coy’s were
purchased from Sigma Chemicals (Buchs, Switzerland). Fetal
bovine serum (FBS) was from Biochrom AG (Berlin, Germany).
Insulin, cycloheximide (CHX), PD098059, Sodium Dichloroace-
tate (DCA), Sodium L-lactate and 5,6-dichlorobenzimidazole 1b-
D-ribofuranoside (DRB) were purchased from Sigma-Aldrich
(Fluka AG, Buchs, Switzerland). The following cell lines were
purchased from ATCC (Manassas, VA): human colon carcinoma
cell line HT-29 (accession number: HTB-38), SW-620 (CLL-227),
HCT116 (CCL-247) and JEG-3 (HTB-36). Akt Inhibitor VIII was
from Calbiochem (Merck, Zug, Switzerland). Adenosine 59-
triphosphate [gamma-32P] ([gamma32P] ATP) was from Perkin
Elmer (Maanstraat, The Netherlands).
Cell Cultures
HCT116, SW-620 and HT-29 were grown in DMEM
supplemented with 10% FBS, 2 mmol/L glutamate, 100 U/ml
penicillin, and 100 mg/ml streptomycin. The cells were main-
tained at 37uC in humidified 5% CO2-95% air. All cell lines were
plated in cell culture dishes and grown in DMEM 10% FBS to
confluence. Cells were incubated in DMEM supplemented with
0.3% FBS during insulin and DCA treatment. Cells were treated
48 h with DCA and 24 h with insulin. Cells were incubated with
10% FBS during lactate treatment after 24 h synchronization in
DMEM 0.3% FBS.
RNA preparation and expression level
Total RNA was isolated using RNeasy Mini Kit (Qiagen AG,
Basel, Switzerland) according to the manufacturer’s protocol.
Total RNA (1 mg) was used for the synthesis of first strand cDNA
using the Improm-II Reverse Transcriptase (RT) in RT buffer
(Promega Catalys AG, Wallisellen, Switzerland) according to the
manufacturer’s protocol. Expression of specific mRNA was
determined by quantitative real-time RT-PCR (qRT-PCR) on
an ABI PRISM 7000 Sequence Detection System (Applied
Biosystems, Foster City, CA). Multiplex PCR was performed
according to the manufacturer’s protocol (Applied Biosystems,
Foster City, CA). Assays-on-Demand (Gene Expression Assay
Mix) were eukaryotic 18S rRNA endogenous control (4310893E),
HSD11B2 (Hs00388669_m1), CCAAT/enhancer binding protein
(C/EBP) alpha (Hs00269972_s1), C/EBP beta (Hs00270923_s1)
and C/EBP delta (Hs00270931_s1). Relative gene expression was
determined using the comparative CT (threshold cycle) method,
which consists of the normalization of the number of target gene
copies to an endogenous reference gene (18S rRNA), designated as
calibrator. The level of HSD11B2, C/EBP alpha, C/EBP beta
and C/EBP delta mRNA expression of each of the treated cells
was normalized to the result obtained from untreated cells. The
amount of target normalized to the 18S rRNA endogenous
reference is given by the formula: 22DDCT. To confirm the
reproducibility of mRNA determination, a minimum of 3
independent total RNA extractions were performed. Each
reverse-transcriptase polymerase chain reaction (RT-PCR) assay
was analyzed in triplicate and expressed as mean +/2 SD.
Measurement of 11beta-HSD2 activity
Cells were cultured in 6-well plates at a density of 0.56106 cells/
well. After treatment, culture medium was removed and cells were
incubated for 45 min in 1 ml medium containing 2 mCi of
[1,2,6,7-3H] Cortisol (60–80Ci/mmol, Amersham, Buckingham-
shire, UK) in 6-well plates. After incubation the reaction was
stopped and the steroids were extracted by the addition of three
volumes of ethyl acetate. After centrifugation, the organic phase
was removed and evaporated at room temperature. The residue
was reconstituted in 30 ml of stop solution (2 mM cortisol and
2 mM cortisone in methanol). Ten microliters were applied to
silica–coated TLC plates (G-25, UV254, Macherey-Nagel,
Oensingen, Switzerland) and resolved using chloroform: ethanol
(9:1). Steroids were visualized under ultraviolet light and were
scraped into scintillation fluid. The radioactivity was measured
using a Packard 2000CA Tri-Carb Liquid Scintillation Analyzer
(Packard Instrument Co, Downers Grove, IL). Experiments were
carried out under non-substrate limiting conditions, where
metabolism was always less than 40%. Specific activity was
expressed as picomoles (pmoles) per micrograms of protein per
hour. The experimental results were calculated by expressing the
conversion rates of cortisol to cortisone in the presence of insulin,
as a percentage of that in the corresponding control in absence of
insulin [15].
Western blot analysis
Protein extraction and Western blot analyses were performed as
reported earlier [16]. Briefly, nuclear extracts were isolated with
the CelLytic NuCLEAR Extraction protocol (Sigma Chemicals,
Buchs, Switzerland). For Western blot analysis, total protein
(100 mg) and nuclear extracts (60 mg) were loaded on a denaturing
10% polyacrylamide gel. The membrane was blocked overnight
and incubated with rabbit polyclonal antibody for 11beta-HSD2
(H-145,1:500), C/EBP alpha (sc-61X, 1:5000), C/EBP beta (sc-
150X, 1:5000), b-actin (sc-1616R, 1:500) or HDAC1 (sc-7872,
1:500) (Santa Cruz Biotechnology, Santa Cruz, CA). Washed
nitrocellulose membranes were incubated with a goat anti-rabbit
IgG horseradish peroxidase conjugate (sc-2004, Santa Cruz
Biotechnology, Santa Cruz, CA) and developed using enhanced
chemiluminescence (ECL) reagent (Amersham, Buckinghamshire,
UK). Densitometry of exposed films was performed and the level
of protein expressed as arbitrary units.
For detection of IGF1 and insulin receptors cells were either
untreated or treated with 100 nM insulin for 24 h and lysed in
RIPA buffer containing 1 mM sodium orthovanadate, 2 mg/ml
aprotinin, 1 mg/ml leupeptin, 1 mM phenylmethanesulfonyl
fluoride. The lysates were incubated with either IGFR or Insulin
Receptor antibodies (3027, 3025, Cell Signaling) at 4uC overnight.
In the morning, the samples were incubated with Protein A/G
Plus Agarose (Santa Cruz Biotechnology) for 1 h at 40uC. The
beads were washed, boiled in SDS loading buffer and proteins
were separated by SDS-PAGE.
De novo protein synthesis
HT-29 cells were cultured as outlined above and pretreated
with the protein synthesis (or translational elongation) inhibitor,
CHX (10 mM) for 1 h before the addition of insulin (1027 M). At
the end of the 24 h treatment, cells were harvested for RNA
isolation and qRT-PCR analysis.
HSD11B2 mRNA stability
HT-29 cells were cultured as outlined above and treated with
insulin (1027 M) for 12 h. Transcription was stopped with DRB
(25 mM) and cells were harvested at discrete times (0–12 h) for
RNA isolation and qRT-PCR analysis.
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Small interfering RNA (siRNA) experiments
HT-29 cells were transiently transfected using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) following the manufactur-
er’s recommendations. The transfection mixture was removed
after 24 h incubation. The cells were further incubated under
normal growth conditions for another 24 h before mRNA
extraction. The siRNA duplexes for C/EBP alpha or C/EBP
beta (Qiagen AG, Basel, Switzerland) and a negative control
siRNA (Invitrogen, Carlsbad, CA, USA) were used for transfection
at a final concentration of 50 nM.
Electrophoretic mobility shift assay (EMSA) and nuclear
extract preparation
Around five million of adherent cells were detached with 3 ml of
PBS on ice and were pelleted for 5 min at 900 g. Pellets were
stored at 280uC until protein extraction. Nuclear extract
preparation and EMSA were performed as previously described
[17,18]. The protein yield was determined by the Bradford
method. EMSA probes were generated by annealing complemen-
tary single-stranded oligonucleotides and labeled with [gamma32P]
ATP and T4 polynucleotide kinase. Specific binding was
competed with unlabeled oligonucleotides which sequence is
recognized by the C/EBP factors at a 100X-molar excess (59-
tgcagattgcgcaatctgca-39; the nucleotide motifs of interest are
bold-faced). The binding reactions were carried out in 10 ml of
buffer [20 mM HEPES, pH 7.5; 35 mM NaCl; 60 mM KCl;
0.01% NP 40; 2 mM DTT; 0.1 mg/ml BSA; 4% ficoll] containing
1.75 pmol of labeled probe, 4 mg nuclear proteins and 1 mg poly
(dI-dC). Mixtures were incubated at 4uC for 20 min in presence or
absence of unlabeled competitor. DNA-protein complexes were
separated on a 5% polyacrylamide gel in 0.56Tris-borate-EDTA
buffer for 90 min at 140 V. Gels were dried 2 h at 80uC and
analyzed on a PhosphoImager Cyclone (Packard).
Chromatin immunoprecipitation
ChIP assays were performed according to the instruction of
Upstate Biotechnology Inc as previously reported [18]. Purified
DNA fragments were amplified with PCR primers to detect a
210 bp fragment containing the 2177C/EBP, -198C/EBP sites
within the HSD11B2 promoter (forward: 59-GCAACTTTGG-
GACTTTGTTCCGGC-39; reverse: 59-AGAGGGACACTCGC-
TTTCTCTGCT-39).
qRT-PCR analysis using human diabetes RT2 Profiler PCR
Arrays
The RT2 Profiler PCR Arrays PAHS-30C (SA Biosciences,
MD, USA) was designed to analyze 84 genes related to human
insulin signaling pathway. The RT-PCR was carried out using an
ABI PRISM 7000 Sequence Detection System (Applied Biosys-
tems, Foster City, CA). HT-29 cells were treated for 24 h with
insulin (1027 M). Total RNA (1 mg) was used as template to
synthesize cDNA with the RT2 First Strand kit (SABiosciences).
The PCR cycle condition was as follows: 95uC for 10 min,
followed by 40 cycles of 95uC for 15 s, 60uC for 60 s. At the end of
PCR cycling steps, data for each sample were displayed as a
melting curve. The ABI SDS software (Applied Biosystems) was
used to determine a critical threshold (Ct), which was the cycle
number where the linear phase for each sample crossed the
threshold level. Beta-2-microglobulin was used as housekeeping
gene. The expression of HSD11B2 for the 3 experiments
concerned was monitored in parallel by real time PCR which
confirming significant downregulation by insulin. Records were
deposed in the GEO data base with accession number GSE51677.
Transient transfection and reporter gene assay
Transfections were performed with FuGENE HD transfection
reagent (Roche, Rotkreuz, Switzerland) using 3 ml of solution for
1 mg of plasmid. The vector pCMV-hRL (Renilla reniformis
luciferase) (Promega Catalys AG, Wallisellen, Switzerland) was
used for normalization of transfection efficiency. The construct
p4.5 kb-HSD11B2 was a generous gift from de. K. Yang [19].
The p0.2 kb-HSD11B2 plasmid construct was described previ-
ously [18]. For expression of transcription factors, various amounts
of the vectors pCMV-LIP and pCMV-LAP, a generous gift from
U. Schibler [20], were added to the DNA mixture. After 6 h the
transfection medium was replaced with normal growth medium
for 18 h. Thereafter cells were lysed and luciferase activities were
detected with the Dual-Luciferase Reporter Assay System
(Promega Catalys AG, Wallisellen, Switzerland) and Media-
torsPhL Luminometer (Mediators Diagnostic Systems, Vienna,
Austria). Firefly luciferase activity was expressed relative to Renilla
luciferase to account for differences in transfection efficiency.
When a CMV-LacZ control vector was transfected, Dual-Light
system (Applied Biosystems, Foster City, CA) was used to
determine the luciferase activity. Transfections were confirmed
by multiple independent experiments.
Site-directed mutagenesis
HSD11B2 promoter mutants were generated in the p4.5 kb-
HSD11B2 and p0.2 kb-HSD11B2 constructs using QuikChange
II XL site-directed mutagenesis kit (Stratagene, Basel, Switzer-
land). The following primers were used: 59-GTGGAACTTGA-
GAGCTCGAGCAGTTCCCTTCACCTCTGG-39 and 59-
CCAGAGGTGAAGGGAACTGCTCGAGCTCTCAAGTTC-
CAC-39 for -4362 C/EBP and 59-CTCGAGCGCAGCCGCTC-
CAGGACTTTGTTCCGGCTTTTTC-39 and 59- GAAAAAG-
CCGGAACAAAGTCCTGGAGCGGCTGCGCTCGAG- 39
for -198 C/EBP. Underlined and bolded letters represent
mutated bases.
Bioinformatics and statistics
Data are expressed as mean +/2 SD of triplicate samples of a
representative experiment repeated at least three times. Statistical
analysis was performed using the Student’s t test or ANOVA
analyses and was followed by a contrast test with Tukey error
protection. Differences were considered significant at p,0.05, *p,
0.05, **p,0.01, ***p,0.001. Transcription factor binding sites
were analyzed with the Match program.
Figure 1. Sustained insulin treatment diminished the 11beta-HSD2 expression and activity in HT-29 cells. (A) 11beta-HSD2 activity was
measured by 3H-cortisol/cortisone conversion assay in colonic cell lines 24 h after incubation with insulin (10211–1027 M). The activity measured for
HCT116 in absence of insulin was set as 100%. (B) Dose-response effect of insulin (1029–1025 M) on HSD11B2 mRNA (gray bars) and activity (curve) in
HT-29 cells treated for 24 h. (C) Time-dependent effect of insulin (1027 M) on HSD11B2 mRNA (gray bars) and activity (curve) in HT-29 cells. (D) Time-
dependent effect of insulin (1027 M) on 11beta-HSD2 protein level.
doi:10.1371/journal.pone.0105354.g001
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Figure 2. Insulin-dependent decrease of 11beta-HSD2 activity and mRNA is reversible but HSD11B2 half-life is not affected. (A)
11beta-HSD2 activity was measured in HT-29 cells in presence (black bars) and absence (white bars) of 1027 M insulin for 24 h. The insulin effect was
reversible on washout with PBS 24 h or 48 h of follow-up (hatched bars). (B) HSD11B2 expression was assessed by qRT-PCR in HT-29 pretreated with
the protein synthesis inhibitor CHX (10 mM) for 1 h and treated with insulin (1027 M) for 24 h. Each data point is expressed as a percentage of the
control value. (C) HT-29 cells were pretreated with (filled circles) or without (filled rhombus) insulin (1027 M) for 12 h. The cells were then treated with
25 mM of the mRNA synthesis inhibitor DRB, without or with insulin (1027 M) (defined as time zero). At the indicated time points thereafter, total RNA
was isolated, and the steady state level of HSD11B2 mRNA assessed. Each data point is expressed as a percentage of the maximum determined at
time zero.
doi:10.1371/journal.pone.0105354.g002
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Results
Sustained insulin treatment decreases 11beta-HSD2
activity and HSD11B2 gene expression in colonic cancer
cell lines
Regulation of enzyme activity by insulin was examined in
HSD11B2 expressing [16–18,21] human colonic cell lines
(HCT116, SW620 and HT-29) (Fig. 1A). Cells were incubated
for 24 h with insulin (10211 M-1027 M) in cell culture medium
containing 0.3% FBS. Insulin caused a dose response decrease in
11beta-HSD2 activity in all tested colonic cell lines with a
significant reduction at 1029 M in HCT116 cell line (p,0.05).
This effect was not restricted to colonic cell lines since similar
results were obtained with HSD11B2 expressing [19] JEG-3 cells
(Fig. S1). Due to the robust response (<30% reduction), we further
characterized the molecular mechanisms in HT-29 cells.
Sustained insulin treatment decreases HSD11B2 gene
expression, activity and protein in HT-29 cells in a dose-
and time-dependent manner
We next confirmed whether insulin-reduced 11beta-HSD2
activity coincides with its gene and protein expression (Fig. 1A).
Increasing concentrations of insulin ranging from 1029 to 1025 M
caused a concentration-dependent decrease in HSD11B2 mRNA
levels 24 h after treatment (Fig. 1B). A maximal effect was
observed at concentration of 1027 M, where HSD11B2 mRNA
was lowered by 50% (p,0.05) (Fig. 1B); and the activity by 35%
(p,0.05) (Fig. 1B). Thereafter, we investigated the time-dependent
regulatory effect of insulin on HSD11B2 gene expression, activity,
and protein level. As shown in Figure 1C, a time-dependent
decrease in 11beta-HSD2 activity was observed with a significant
reduction 12 h after treatment (p,0.05). Interestingly the
Figure 3. Insulin activates insulin and IGF-1 receptors and PI3K/AKT – MEK downstream pathways. (A) Expression and phosphorylation
of insulin receptor by insulin in a time (0 to 60 min) and dose (0 to 1000 nM) dependent manner. (B) Expression and phosphorylation of IGF-1
receptor by insulin in a time and dose dependent manner. (C) HSD11B2 mRNA expression monitored by qRT-PCR in presence of insulin, AKT inhibitor
(AKTVIII, 0.1 mM and 10 mM) or MEK inhibitor (PD098059, 1 mM).
doi:10.1371/journal.pone.0105354.g003
Figure 4. Schematic representation of the insulin pathway and its regulation by sustained insulin stimulation in HT-29. mRNAs were
quantified 24 h after insulin (1027 M) treatment using RT2 Profiler PCR Arrays PAHS-30C. Up-regulated transcripts are shown in red and down-
regulated transcripts are shown in green.
doi:10.1371/journal.pone.0105354.g004
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HSD11B2 mRNA increased during the first 10 h and decreased
thereafter. After 16 h the mRNA reached minimal levels and
remained low up to 48 h (p,0.05) (Fig. 1C). In agreement,
HSD11B2 protein was reduced by 18 h and 24 h of insulin
treatment (Fig. 1D).
The downregulation of HSD11B2 was reversible by removing
insulin from the medium 24 h after incubation. Indeed, 48 hours
after the removal, HSD11B2 mRNA levels in control and insulin
treated conditions were similar (Fig. 2A). Next, HT-29 cells were
treated 24 h with insulin in the absence and presence of the
protein synthesis inhibitor, cycloheximide (CHX). The effect of
insulin in reducing HSD11B2 mRNA was abolished in the
presence of CHX, indicating that de novo protein synthesis was
required (Fig. 2B). To determine whether insulin reduces the
HSD11B2 mRNA stability, we assessed the half-life of HSD11B2
mRNA by a standard mRNA decay assay using 25 mM DRB, an
inhibitor of mRNA synthesis. As shown in Figure 2C, insulin did
not alter the half-life of HSD11B2 mRNA.
Insulin pathway analysis
In order to understand the molecular mechanism by which
insulin down-regulates HSD11B2 we aimed to characterize the
insulin pathway in HT-29. Western blot experiments demonstrat-
ed the expression and activation of IGF-1 (IGFI-R) and insulin
receptors (IR) in a time and dose dependent manner (Figs. 3 A, B).
Both receptors are phosphorylated within the first 10 min upon
insulin treatment, while IR was more sensitive than IGFI-R to low
doses of insulin (Figs. 3 A, B). The role of downstream kinases on
insulin-dependent HSD11B2 repression was assessed using
PD098059 and AKT VIII inhibitors. Figure 3C shows that both
pathways, the MAPK/ERK and the PI3K pathway, mediated the
insulin effect.
Total mRNA of insulin treated HT-29 cells was extracted and
subjected to RT2 profiling to quantify the expression of insulin
pathway components. The Human Insulin Signaling Pathway
RT2 Profiler PCR Array profiles the expression of 84 genes related
to insulin-responsive genes. Twenty two genes differentially
regulated in HT-29 cells after insulin treatment are reported in
Table S1 and the pathways involved are depicted in the scheme of
Figure 4. RT2 profiler revealed a characteristic pattern of insulin
insensitivity, with reduced expression of insulin pathway compo-
nents: IR, IGFI-R, insulin receptor substrate (IRS2) and insulin
regulated glucose transporter (GLUT-4). Sustained insulin treat-
ment also promoted glycolysis in HT-29 cells. While insulin
regulated glucose transporter GLUT-4 expression was downreg-
ulated, GLUT-1 encoding messenger was increased, facilitating
the import of glucose into the cells, independently of growth factor
stimulation. Hexokinase 2, the enzyme which phosphorylates
glucose to glucose-6-P, a rate limiting step of glycolysis, was up-
regulated, along with pyruvate kinase 2 (PKM2), which converts
PEP into pyruvate. In contrast, the enzyme which dephosphor-
ylated fructose 1, 6 bisphosphate into fructose-6-phosphate and
contributed to antagonizing glycolysis was downregulated.
Effect of insulin on C/EBP alpha, C/EBP beta, and C/EBP
delta mRNA levels
We present evidence in Figure 5B, that treatment of HT-29
cells with various concentrations of insulin (1029–1025 M) for
24 h caused a concentration-dependent increase in C/EBP beta
mRNA expression. In contrast, insulin suppressed the expression
of C/EBP alpha mRNA expression in a dose-dependent manner.
At a concentration of 1027 M, insulin decreased the C/EBP alpha
mRNA by 51% (p,0.01), whereas C/EBP delta mRNA
expression was unchanged. These results show that insulin-
dependent reduction of HSD11B2 mRNA, correlates with the
expression pattern of 2 out of 3 investigated members of the C/
EBP family of transcription factors in HT-29 cells.
Insulin-regulation of C/EBP alpha and C/EBP beta
proteins
To investigate whether C/EBP alpha or C/EBP beta play a role
in the insulin-dependent repression of HSD11B2 gene expression,
the expression of C/EBP alpha and C/EBP beta in HT-29 cells
were analyzed by Western blots (Fig. 5A). C/EBP alpha mRNA
may lead to two polypeptides with a size of 42 kDa and 30 kDa
[22,23] while C/EBP beta might evolve to an activating or an
inhibitory isoform (LAP, 38 kD or LIP, 21 kDa, respectively)
[20,24]. Treatment of HT-29 cells with insulin for 24 h increased
the nuclear levels of C/EBP alpha (isoform 42 kDa), of both C/
EBP beta isoforms LAP and LIP, and decreased the nuclear levels
of C/EBP alpha (isoform 30 kDa) in a dose-dependent manner. In
parallel the expression of HSD11B2 decreased concomitantly with
a maximal effect obtained at 1026 M of insulin (Fig. 5A).
However, in response to the same dose of insulin, the increase
in LIP (<130 fold at 1026 M insulin) was greater than that in LAP
(<3 fold at 1026 M insulin), resulting in a decreasing LAP/LIP
ratio (Fig. 5A). Expression of C/EBP alpha (isoform 42 kDa) was
slightly increased while the expression of C/EBP alpha (isoform
30 kDa) was decreased by 50% (Fig. 5A).
HSD11B2 gene expression is up-regulated by C/EBP
alpha/beta silencing
The effect of C/EBP alpha/beta knockdown on HSD11B2 was
assessed in HT-29 cells. There is evidence from this siRNA
transfection experiment that C/EBP alpha and C/EBP beta
mRNA was downregulated significantly (Fig. 5C, D, left panel).
Importantly, the mRNA levels of HSD11B2 increased following
transfection with siRNA against both isoforms (Fig. 5C, D, right
panel).
Figure 5. Insulin-dependent regulation of the 11beta-HSD2 protein level and role of the CCAAT/enhancer-binding protein (C/EBP)
family. (A) Concentration-dependent effects of insulin on 11beta-HSD2, C/EBP alpha, and C/EBP beta protein levels. HT-29 cells were cultured for
24 h without and with increasing concentrations of insulin (1029–1025 M), then harvested for Western blotting to evaluate expression of 11beta-
HSD2, C/EBP alpha, C/EBP beta. (B) Concentration-dependent effects of insulin on C/EBP alpha, C/EBP beta, and C/EBP delta mRNA expression. HT-29
cells were treated like in (A). The level of C/EBP alpha (open circles), C/EBP beta (open squares), and C/EBP delta (filled triangles) mRNA was measured
using qRT-PCR with S18 as internal control. Expression levels in treated cells were normalized to untreated controls (100%). Representative data for at
least three independent experiments. The relative intensity was determined by densitometric scanning. The ratio of relative densities of 11beta-HSD2
to beta-actin in cells cultured in the abscence of hormone was considered as 100% (control). The ratio of relative densities of nuclear extract proteins
to HDAC in cells cultured without hormone was considered as 100% (control). * LIP was undetectable in the control samples, so the LAP/LIP ratio was
not calculated. (C, D) Silencing of C/EBP alpha (C) and C/EBP beta (D) was performed using siRNA. The expression of C/EBP alpha, C/EBP beta (left
panel) and HSD11B2 (right panel) mRNA was measured using qRT-PCR.
doi:10.1371/journal.pone.0105354.g005
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Figure 6. Binding of C/EBP alpha/beta on human HSD11B2 promoter. (A) Nuclear proteins isolated from HT-29 cells bind to identified C/EBP
alpha/beta sites.4 mg of nuclear extracts isolated from insulin treated (for the indicated period of time, 1027 M) or untreated HT-29 cells were
incubated with radiolabeled probe encompassing the consensus C/EBP alpha/beta site in the presence or absence of non-radiolabeled (1006)
competitor probe (cons C/EBP alpha/beta or mut C/EBP alpha/beta) (lanes1–7). Arrows indicate C/EBP alpha/beta / DNA shifts (C1, C2, C3) separated
from free probe by gel electrophoresis. The complex C3 is formed in presence of radiolabeled 2198 C/EBP alpha/beta probe (lanes 14–17) while
complex C2 is formed in presence of radiolabeled 24362 C/EBP alpha/beta probe (lane 22–25). (B) Nuclear proteins isolated from HT-29 cells bind to
the consensus SP1 site. Nuclear extracts isolated from insulin treated (for the indicated period of time, 1027 M) or untreated HT-29 cells were
incubated with radiolabeled probe encompassing the consensus SP1 site with and without non-radiolabeled (100X) competitor probe (cons SP1, lane
5or mut SP1, lane 6). The arrow indicates SP1/DNA shifts separated from free probe by gel electrophoresis. The complex intensity increased modestly
with insulin treatment. The specific shift was abolished by the cold cons SP1 probe (lane 5) while not affected when mut SP1 probe was used as
competitor (lane 6). (C) Chromatin immunoprecipitation (ChIP) analysis of C/EBP alpha and C/EBP beta during insulin stimulation in HT-29 cells. ChIPs
were performed from untreated (W/O) and insulin induced (1–24 h) HT-29 cells using antibodies specific for C/EBP alpha (middle panel) and C/EBP
beta (bottom panel), a no-antibody control (NO). The precipitated chromatin was analyzed using primers specific for the human HSD11B2 promoter.
The DNA fragments were amplified with PCR primers to detect a 210 bp fragment containing the potential 2177 and 2198 C/EBP sites within the
HSD11B2 promoter. Input chromatin is represented in upper panel.
doi:10.1371/journal.pone.0105354.g006
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Insulin regulation of C/EBP-DNA complexes
The in silico analysis of the human HSD11B2 gene promoter
sequence revealed 4 putative binding sites for C/EBPs located at
positions 24361, 21985, 2198 and 2177 bp from the transcrip-
tional start site (Table 1). The site 24361 has the higher match
with the consensus sequence (Table 1). Different probes were
labeled and incubated in presence of nuclear extracts isolated from
insulin treated HT-29 cells. EMSA performed with the probe
containing the consensus C/EBP binding site revealed three
specific complexes (Fig. 6A, lane 1, noted C1-3). The signals were
reversed by competition with the unlabelled probe harboring the
consensus C/EBP site (Fig. 6A, lane 6) while unaffected when the
probe harbored the mutated C/EBP sites (Fig. 6A, lane 7).
Therefore, C1-3 signals might correspond to C/EBP/DNA
complexes. The C/EBP binding to the consensus probe was
elevated with increased duration of insulin treatment (Fig. 6A,
lanes 1–5) reflecting the increased level of C/EBP beta found by
Western Blot (Fig. 5A). Interestingly, the intensity of C2 increased
more than C1, C2 being more abundant relatively to C1 24 h
after insulin treatment than in controls (lanes 1, 5).
The probes 2198 and 24361 (Table 1) elicited the formation
of complexes C2 or C3, but lacked C1 (Fig. 6A, lanes 14, 22).
Complex formation were increased with insulin, albeit modestly
for2198 (Fig. 6A, lanes 15, 23), and were reversed by competition
with the probe harboring the consensus C/EBP site (Fig. 6A, lanes
16, 24). The complexes formed with 2177 and 21985 were weak
and not specific.
The binding of SP1, a transactivating factor known to regulate
HSD11B2 expression [25], to its consensus binding site (Table 2)
occurred in the unstimulated condition and was slightly increased
upon insulin treatment (Fig. 6B, lane 1–4), suggesting that this
factor might not be involved in the HSD11B2 repression upon
insulin stimulation.
Considering the original pattern of the complexes formed with
the probe 2198, a ChIP assay was performed, which actually
confirms the binding of CEBP isoforms. Upon insulin treatment,
CEBP beta binding to HSD11B2 promoter increased in a time
dependent manner, while CEBP alpha interaction decreased
(Fig. 6C), in agreement with the level of respective proteins
(Fig. 5A).
Modulation of HSD11B2 promoter activity by C/EBP beta
isoforms
To confirm the importance of the LAP/LIP ratio in the
regulation of HSD11B2 gene expression at the transcriptional
level, we used a reporter assay (Fig. 7). The construct p4.5 kb-
HSD11B2 encompasses the region 24.5 kb to +0.116 kb of the
human HSD11B2 promoter cloned in front of the luciferase
encoding plasmid pGL3. Luciferase activity was measured as an
indicator of HSD11B2 promoter activity. The construct, p4.5 kb-
HSD11B2 was co-transfected into HT-29 cells with the plasmids
encoding the long isoform of C/EBP beta (LAP) alone or in
combination with the short isoform (LIP). We used the pcDNA-
LAP/pcDNA-LIP plasmid DNA ratio to represent the LAP/LIP
ratio in transfected cells, while keeping the total amount of plasmid
transfected constant (pcDNA3 empty vector was used to compen-
sate DNA quantities). The luciferase activity correlated with the
amount of pcDNA-LAP transfected (Fig. 7A). In contrast,
increasing LIP expression decreased luciferase activity (Fig. 7B).
To validate the role of characterized C/EBP beta binding sites,
mutagenesis was performed. By mutating the sites 24392 and
2198, the basal (Fig 7C) and the LAP (Fig 7D) induced promoter
activities were partly reduced. This data suggested that several
Table 1. Probes used for the EMSA experiments with C/EBP.
Matrix C/EBP A(G/C)T(A)T(G/A)G(A/T) C(G/A) G(C/A)C(A/T)A(C)AT(G/A)
cons C/EBP 59-tgcagATTGCGCAATctgca-39 (100%)
mut C/EBP 59-tgcagAGACTAGTCTctgca-39 (20%)
2177 C/EBP 59-tccggctTTTTCCAAATcgaatct-39 (60%)
2198 C/EBP 59-aaCTTTGGGACTttgttccg-39 (50%)
21985 C/EBP 59-tcctgCTTTAGCAAGtgctg-39 (60%)
24361 C/EBP 59-gagagCTTGAGCAATtccct-39 (80%)
The weight matrix for the consensus C/EBP alpha/beta binding motif is given on top. The consensus C/EBP alpha/beta binding motif was aligned with the potential C/
EBP binding sites identified in the human HSD11B2 promoter and located at position 2177, 2198, 21985, 24362 bp. ‘‘cons C/EBP’’ and ‘‘mut C/EBP’’ designate 20 to
24-mer oligonucleotides based respectively on the consensus and mutated binding site for C/EBP. Mismatched nucleotides with matrix are underlined. In bold are the
nucleotides identical to the consensus sequence and the percentage of match with the consensus sequence is indicated.2177 C/EBP,2198 C/EBP,21985 C/EBP,24362
C/EBP indicate the probes harboring the putative binding sites for C/EBP alpha/beta located in the human HSD11B2 promoter.
doi:10.1371/journal.pone.0105354.t001
Table 2. Probes used for the EMSA experiments with SP1.
Matrix SP-1 G(A/T)G(A)GG C(A/T)GG G(A/C)
cons SP-1 59-attcgatcGGGGCGGGgcgagc-39 (100%)
mut SP-1 59-attcgatcGGTTCGGGgcgagc-39 (80%)
The weight matrix for the consensus SP1 binding motif is given on top. ‘‘cons SP1’’ and ‘‘mut SP1’’ designate 22-mer oligonucleotides based respectively on the
consensus and mutated binding site for SP1. Mismatched nucleotides with matrix are underlined. In bold are the nucleotides identical to the consensus sequence and
the percentage of match with the consensus sequence is indicated.
doi:10.1371/journal.pone.0105354.t002
Insulin-Dependent Regulation of HSD11B2
PLOS ONE | www.plosone.org 11 August 2014 | Volume 9 | Issue 8 | e105354
Figure 7. C/EBP beta isoforms control HSD11B2 promoter activity. (A) HT-29 cells were transfected with the full length human HSD11B2
promoter cloned into pGL3-basic luciferase vector (p4.5 kb-HSD11B2, 400 ng) and a dose response of LAP expressing vector (pCMV-LAP, 6.25 to
400 ng). A schematic representation of the promoter of HSD11B2 is shown on the left side. The transcriptional initiation site is indicated by an arrow
(+1). The empty pcDNA3 vector was used to equalize the amount of transfected DNA in every condition and the pCMV-hRL (100 ng) was used as
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binding sites participated in the C/EBP mediated HSD11B2
promoter activity. Surprisingly, the reporter assay experiments
failed to show any insulin-dependent regulation of HSD11B2
promoter, suggesting that insulin action might be mediated at an
epigenetic level.
The insulin-dependent lactate synthesis modulated
11beta-HSD2 activity
Next, we challenged the hypothesis that lactate, a potential
HDAC inhibitor and a byproduct of glycolysis, which is increased
under insulin stimulation mediates HSD11B2 downregulation.
Lactate secretion was quantified under insulin treatment and
11beta-HSD2 activity monitored under lactate stimulation or
lactate synthesis blockage. Figure 8A shows a dose dependent
increase in lactate secretion by insulin in HT-29 cells. Treatment
with lactate alone significantly reduced 11beta-HSD2 activity in
HT-29 and HCT116 cells (Fig. 8B). Dichloroacetate (DCA) is a
pyruvate dehydrogenase kinase (PDK) inhibitor, whose action
restores the normal oxidative demolition of pyruvate and thus
indirectly preventing glycolysis [26]. Used alone, DCA reduced
lactate production in HT-29 (Fig. 8C) however, in combination
with insulin, it reduced insulin-dependent stimulation of lactate
secretion (Fig. 8C). Most importantly, DCA reduced insulin-
dependent downregulation of 11beta-HSD2 activity (Fig. 8D).
Discussion
Insulin-dependent regulation of HSD11B2
The present investigation revealed in three different human cell
lines, that insulin reduces the activity of 11beta-HSD2. We report
for the first time, that the dose- and time-dependent effect of
insulin is attributable to diminished transcriptional activity, as
opposed to the stability of the transcribed mRNA. A peculiar
finding of the insulin-induced down-regulation of HSD11B2 is the
increase in mRNA levels during the first 8–10 h, without a
concomitant increase in the activity or protein content (Fig. 1C),
an observation previously made for C/EBPs. The mechanism for
this discrepancy is unknown. One possible explanation might be
the temporal induction of small regulatory RNA molecules,
interfering with transcription, as it has recently been demonstrated
for GLUT-4, hormone sensitive lipase, fatty acid-binding protein
ap2 and peroxisome proliferator-activated receptor gamma 2
genes [27,28].
Mechanisms accounting for insulin-dependent HSD11B2
downregulation
Our study suggests that an insulin-dependent decrease in
HSD11B2 expression could be related to changes in the LAP/LIP
ratio, chromatin structural changes or lactate production.
1-Considering decreased LAP/LIP ratio to inhibit
HSD11B2 expression. An in silico analysis of the HSD11B2
promoter predicted binding-sites for C/EBPs. This is important
since insulin is known to modulate the expression of two isoforms
of C/EBP beta, LAP and LIP [10,11,23,29]. LAP/LIP ratio is
modulated by mTOR, a downstream target of the insulin
pathway, shifting C/EBP translation toward LIP translation
[24]. We made the interesting observation that mTOR and
AKT VIII inhibitor rescued HSD11B2 expression. Moreover,
EMSA experiments demonstrated that following insulin stimula-
tion, there was an increased association of C2 product to the
HSD11B2 promoter. According to the literature this C2 product
comprises a LAP/LIP dimer [20,30]. These correlations were
ascertained by reporter assays showing i) an up-regulation of the
promoter activity concomitant with LAP overexpression, ii) the
requirement of both non-canonical C/EBP binding sites for the
promoter activity, and iii) the sensitivity of the reporter construct
towards the C/EBP beta LAP/LIP ratio. Taken together, the data
suggest that C/EBP beta, most probably LAP, regulates the basal
expression of HSD11B2, while LIP mediates insulin dependent
HSD11B2 gene repression. Hence, HSD11B2 expression is
regulated by LAP/LIP ratio in a way similar to HSD11B1 [12,14].
2-Other potential participants for an insulin-dependent
inhibition of HSD11B2 transcription. Despite the important
findings concerning the regulatory role of the LIP/LAP ratio,
some questions still remain in order to understand the mechanism
of the insulin-dependent decrease of the HSD11B2 expression. In
transfected, cells we observed the inability of insulin to downreg-
ulate the expression of reporter gene fused to the HSD11B2
promoter (data not shown). We first hypothesized that by
transfecting a large amount of plasmid into the cells, the number
of cis elements available for C/EBP proteins are far in excess. In
this scenario, the newly synthesized LIP molecules in presence of
insulin had the ability to bind plasmidic DNA without displace-
ment of the bound LAP.
Because HSD11B2 transcription is activated in the first hours
and inhibited in the last hours of insulin treatment, it might be
possible that the stability of the luciferase protein did not reflect the
real time activity of the promoter. Indeed, highly stable reporters
accumulate to greater levels in cells, but their concentrations
change slower relative to changes in transcription. Additional
experiments, in which the promoter of HSD11B2 is cloned into a
plasmid encoding for an unstable reporter gene, including for
example a PEST signal, would challenge this hypothesis.
Moreover, gene repression is sometimes dependent on chro-
mosome-embedment and additional sequences located either far
away from the promoter in 59 as described for the PEPCK gene
promoter under insulin treatment [31], or even within the 39
region in the intronic sequence might account for the insulin-
dependent downregulation of HSD11B2. A sequence alignment
using the VISTA program shows some sequences well conserved
in intron I that could potentially act as intronic enhancers (Fig. S2)
[32].
Furthermore, gene expression is also regulated by histones and
DNA wrapping. Yet, transiently transfected DNA acquires a
conformation, structurally different for the counterpart chromatin
integrated DNA that may underlie the differences in the
mechanisms of activation of the two templates [33]. Hence, we
cannot exclude that epigenetic mechanisms (i.e. histone deacetyla-
tion and DNA methylation) are involved in the insulin-dependent
HSD11B2 downregulation. In line with this, HSD11B2 gene
contains 2 CpG islands within the promoter that indeed regulate
gene expression [34]. Moreover, C/EBP beta is known to
cooperate with coactivators such as SWI/SNF which only work
in chromosome-embedded gene [35].
transfection efficiency control. Cells were lysed for luciferase assays 24 h after transfection, and the reading were normalized by renilla activity. (B) HT-
29 cells were transfected with the plasmids p4.5 kb-HSD11B2 (400 ng), pRL-CMV (100 ng), pCMV-LAP (50 ng) and an increasing quantity of pCMV-LIP
(50 ng to 400 ng). (C) HT-29 cells were transfected with the wild type p4.5 kb-HSD11B2 and p0.2 kb-HSD11B2 constructs or with the C/EBP mutated
constructs. (D) HT-29 cells were transfected with the wild type p4.5 kb-HSD11B2 or the C/EBP mutated construct together with increasing
concentration of pCMV-LAP.
doi:10.1371/journal.pone.0105354.g007
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3-The potential role of lactate production to inhibit
HSD11B2 transcription. Interestingly, mRNA profiling un-
derlined the reprogramming of the transcriptome from insulin
sensitive cells towards insulin insensitive cells, with activation of the
glycolytic pathway and consequently lactate production (Table S1,
Fig. 4). In line with the literature, lactate secretion and pH
changes were monitored in HT-29 cells upon insulin treatment
[36]. On one hand, a decrease in pH was shown to inhibit 11beta-
HSD2 activity in kidney tubules directly [37], while on the other
hand, lactate was shown to inhibit HDAC activity directly and by
this fact to regulate gene expression in HCT116 [38]. The 153
gene probes, including HSD11B2, down-regulated by all four
HDAC inhibitors are listed (Supplementary Table 2 of [38]). In
agreement with this observation, an inhibition of lactate synthesis
by DCA reduced significantly the insulin effect, while treatment
with lactate repressed 11beta-HSD2 activity in our cellular models
(HT-29 and HCT116). In this respect, lactate can be considered to
be a potential regulator of HSD11B2 expression, independently or
in parallel to LIP/LAP. This fact is also strengthened by our
previous observation of a decreased HSD11B2 expression along
the rat intestine [39], which is inversely correlated with the
intestinal lactate concentration [40]. Lactate is produced by
bacteria of the gut and is found in the rectum in a millimolar
range, when physiological situations are considered [41]. Our
finding that 11beta-HSD2 activity was decreased using 50mM
lactate, is consistent with the literature [38], although, it is
uncertain if such concentrations could be reached locally in the gut
or if such a down regulation would happen in vivo with longer
exposure and lower amounts. Nevertheless, an increase in the
abundance in lactic acid bacteria, associated with methylation
changes in intestinal cells was reported in type 2 diabetic patients
[42]. Moreover, plasmatic lactate is associated with blood pressure
[43] and type 2 diabetes [44]. In addition, lactate is also produced
(up to 17 mM) during ischemia in kidneys [45]. Notably ischemia
was related to renal tubular dysfunctions with increased blood
pressure and reduced 11beta-HSD2 activity [46]. Finally, lactate,
as an indicator of oxidative capacity, was found to predict incident
diabetes, since oxidative capacity is decreased in type 2 diabetes.
Lactate is therefore strongly related to insulin resistance [47].
Whether decreased oxidative capacity is a cause or consequence of
diabetes is unknown, but the link with HSD11B2 downregulation
has to be strongly considered.
Sodium reabsorption is an important function of the kidney, but
also of the rectal and colonic mucosa [48,49]. This mechanism is
regulated, at least in part, by MR [50], with subsequent activation
of the the amiloride-sensitive epithelial sodium channel (ENaC)
[51,52]. Here, we provide evidence for an insulin-dependent
downregulation of HSD11B2, a prerequisite for cortisol-mediated
MR transactivation leading to an increase in sodium reabsorption
Figure 8. Lactate accumulation in the media upon insulin
stimulation and insulin-dependent down-regulation of 11beta-
HSD2 activity. (A) Dose-response effect of insulin on L-lactate
production in cultured HT-29 cells after 24 h incubation. The
concentration in lactate found in the media of HT-29 cells after 24 h
of culture is reported above the bars (Mean +/2 SEM). (B) 11beta-HSD2
activity in cultured HT-29 and HCT116 cells exposed to exogenous L-
lactate for 3 h. (C) 24 h L-lactate production in cultured HT-29 cells
exposed to DCA alone or in combination with insulin. (D) 11beta-HSD2
activity in cultured HT-29 cells exposed to DCA alone or in combination
with insulin.
doi:10.1371/journal.pone.0105354.g008
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in the colon. All together, these data suggest that the downreg-
ulation of HSD11B2 expression in cancer colonic cell lines, after
long-term insulin treatment would be the consequence of LIP
overexpression, together with increased lactate production, both
working at an epigenetic level. These mechanisms are of interest
and significance for the understanding sodium reabsorption in the
colon in health and disease states.
Supporting Information
Figure S1 Sustained insulin treatment diminished the
11beta-HSD2 expression and actiity in JEG-3 cells. (A)
11beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) expres-
sion was assessed by qRTPCR in SW620 (gray bars), JEG-3
(hatched bars), and HT-29 (filled bars) cells 24 h after incubation
with insulin (1027 M). (B) 11beta-HSD2 activity was measured by
3H-Cortisol/Cortisone conversion assay in SW620, JEG-3, and
HT-29 cells 24 h after incubation with insulin (1027 M).
(TIF)
Figure S2 Sequence homology between human and rat
HSD11B2 genes. Upper part, representation of HSD11B2 gene
with the exons boxed in violet and the untranslated region boxed
in light green. Lower part, percentage of homology between
human and rat sequences. Regions with more than 80% homology
are boxed in green and noted with a or b.
(TIF)
Table S1 Transcriptional regulation of insulin pathway
related genes in HT-29 cells by sustained insulin
stimulation.
(DOCX)
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